AX09 is an innovative antibody-based therapeutic that displays a specific portion of xCT and elicits a significant anti-xCT immune response.

AX09 is an innovative virus-like particle (VLP) that displays a specific portion of xCT and elicits a potent and specific anti-xCT immune response.  VLPs generate strong immune responses due to their optimal size, particulate nature, and intrinsic adjuvant activity.  AgilVax engineered its VLP technology to allow for the precise control of epitope size, structure (loop/linear) and valency to optimize immune responses against xCT.  In vivo, AX09 induces a humoral immune response against xCT that strongly impairs pulmonary metastases formation in mice challenged with tumorspheres-derived breast cancer cells. The characterization of antibodies produced following AX09 immunization formed the foundation for the development of xCT-mAb and xCT-ADC.

In preclinical breast cancer models AX09 impaired tumor growth and reduced metastatic progression with no observed toxicity.